Exelixis, Inc. (NASDAQ:EXEL) stock is currently pricing at roughly $23.15. Our analysis shows that the stock is widely covered by equity research firms, and target prices are revealing. From a summary standpoint, we track the median one-year price target among 5 analysts covering the company at $26.00. That suggests shares of the stock may have another 11 percent to the upside left to run. Of those analysts we surveyed, the highest price target on recordsits at $28.00, which would imply another 79 percent in upside potential. If we look for a little more qualitative data on the range of expectations, we find in analyst notes that the stock has 4 “Buy” ratings in place. At the same time, 2 rate the stock a “strong buy”, suggesting more conviction in the story. As for the doubters, 2 equity research analyst firms call this stock a “Hold” and 0 consider it bad enough to warrant a “Sell” rating.
Analysts at Needham took a look at EXEL shares in a research note released on Mar 31, 2017, and issued a Buy rating to this company. Oppenheimer analysts provided their own take on company recently as well. In a research note published on Mar 16, 2017,the house assigned a Perform rating to this stock. According to a piece that hit the wires on Feb 28, 2017, researchers at Stifel reconsidered their prior rating on the stock, and lowered it from Buy Perform to Hold.
Exelixis, Inc. (EXEL) Cap Table Analysis
Breaking down the capitalization table is our next goal. From a bird’s eye view, Executives hold 1.65 percent of the stock.
If we take a more granular look, Dr. George A. Scangos,PhD is one of the largest owners in company capital stock among insiders. According to U.S. Securities and Exchange Commission (SEC) filings, this investor owns 1,463,648 shares, representing a total current market value of roughly $33883451.2. Dr. Stelios Papadopoulos,PhD is another major player among company insiders, currently holding 1,228,471 shares as of 0.42%, carrying a current market value of $28439103.65. Dr. Lance Willsey,M.D. is currently ranked as the number three insider in terms of representation on the cap table for the stock, holding 568,273 shares, valued at around $13155519.95 as of recent close.
We noted a few insider transactions for the stock recently as well.
In a transaction on 2017-04-03, the company’s Director MARCHESI VINCENT T sold 10,000 company shares for 213000. That means, once accounting for this transaction, the Director is left with a stake of 120,070 shares, carrying a current total market value of $2779621. In addition, by means of a transaction dated 2017-03-31, Director WYSZOMIERSKI JACK L sold 5,150 shares worth $111090. After that transaction, this investor is left with a total holding of 72,960 shares, representing a total investment value of $1689024. We also noted a 2017-03-27 transaction in which EXEL EVP and General Counsel Hessekiel Jeffrey sold 6,884 shares at a stock price of $21.02, carrying a total value of $144700, after which, this insider’s investment stands at 267,946 shares, with an overall financial value of $6202950.
Exelixis, Inc. (NASDAQ:EXEL) Earnings View
In the company’s last quarter, EXEL EPS moved to $0.12 from $-0.04 compared sequentially with the prior quarter. Revenues for the company came in at $77.58MM. This stacks up against $62.19MM, on a sequential basis.
How does this compare with bottom and top-line expectations? Well, according to what we could find, analysts had been looking for the company to post net income of about $-0.01 per share on $66.5MM in revenue. That sets up an interesting next quarter report card. We would note that analysts seem to be projecting earnings, on average, for this quarter in the range of $-0.02 to $0.03. On a year-over-year basis, that compares with an EPS comp of $-0.27.